NCT01368250|UnknownDMC
Loading search results
Sponsor study identifier
observational
20,000
1 country
2
Study Start
February 2011
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
May 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
May 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The purpose of this prospective multi-center, observational national registry in Switzerland is to obtain clinical baseline, procedural and follow-up data of all patients treated with TAVI in Switzerland and to assess short, mid- and long-term clinical outcome data of the CE approved devices. All centers in Switzerland implanting the CE approved devices for TAVI will be invited to include patients in the registry. Each site will collect baseline and procedural data as well as clinical outcome data up to five years.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 2011
Date type not reportedThis date has not been verified as actual or estimated.
June 6, 2011
Actual (reported)June 7, 2011
Actual (reported)May 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
May 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
combined early safety and clinical efficacy as defined by the Valve Academic Research Consortium-2 (VARC-2)
Composed by: * death * stroke * aortic valve re-intervention * structural valve deterioration * myocardial Infarction
1 year
combined early safety and clinical efficacy as defined by the Valve Academic Research Consortium-2 (VARC-2)
30days
combined safety and clinical efficacy as defined by the Valve Academic Research Consortium-2 (VARC-2)
5 years
combined safety and clinical efficacy as defined by the Valve Academic Research Consortium-2 (VARC-2)
10 years , 15 years
Patients with native aortic stenosis undergoing TAVI
Patients with native aortic regurgitation undergoing TAVI
Patients with degenerative surgical bioprosthesis undergoing TAV-in-SAV
Minimal Invasive Implantation of a biological prosthesis in Aortic Position
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients with aortic valve disease or degenerated aortic bioprosthesis scheduled to undergo transcatheter aortic valve implantation (TAVI) using commercially available devices with CE approval are eligible for enrollment in the registry. The TAVI procedure can be performed using all available access routes.
Department of Cardiology
Bern, 3010, Switzerland
Department of Cardiology
Bern, 3010, Switzerland
Tomii D, Alaour B, Heg D, Okuno T, Nakase M, Samim D, Praz F, Lanz J, Stortecky S, Reineke D, Windecker S, Pilgrim T. Self-expanding versus balloon-expandable transcatheter heart valves in patients with excessive aortic valve cusp calcification. Am Heart J. 2026 Feb;292:107279. doi: 10.1016/j.ahj.2025.09.011. Epub 2025 Sep 18.
Badertscher P, Stortecky S, Serban T, Knecht S, Heg D, Tueller D, Jeger R, Reuthebuch O, Muller O, Toggweiler S, Wenaweser P, Huber C, Roffi M, Ferrari E, Reichlin T, Nestelberger T, Mahfoud F, Kuhne M, Sticherling C; SwissTAVI Investigators. Long-Term Outcomes of Patients Requiring Pacemaker Implantation After Transcatheter Aortic Valve Replacement: The SwissTAVI Registry. JACC Cardiovasc Interv. 2025 May 12;18(9):1163-1171. doi: 10.1016/j.jcin.2025.03.028. Epub 2025 Apr 1.
Stefan Stortecky, MD
Bern University Hospital
First Submitted
June 6, 2011
First Posted
June 7, 2011
Study Start
February 2011
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
May 2025
Estimated (date passed)Microembolic Signals and Serum Markers of Neuronal Damage During Transcatheter Aortic Valve Implantation.
Contact the study team to confirm eligibility.
Nakase M, Draxler DF, Tomii D, Heg D, Okuno T, Samim D, Lanz J, Stortecky S, Reineke D, Windecker S, Pilgrim T. Incidence, predictors and clinical impact of upper gastrointestinal bleeding after transcatheter aortic valve replacement. Heart. 2025 Nov 12;111(23):1149-1155. doi: 10.1136/heartjnl-2024-325359.
Tomii D, Heg D, Nakase M, Samim D, Lanz J, Praz F, Stortecky S, Reineke D, Windecker S, Pilgrim T. Flow Status-Based Predicted Prosthesis-Patient Mismatch in Patients Undergoing Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve. Struct Heart. 2024 Dec 6;9(4):100379. doi: 10.1016/j.shj.2024.100379. eCollection 2025 Apr.
Hodel C, Moccetti F, Brunner S, Sandoz V, Loretz L, Wolfrum M, Toggweiler S. Long-Term Outcomes After Transcatheter Aortic Valve Replacement Complicated by New-Onset Persistent Left Bundle Branch Block. Catheter Cardiovasc Interv. 2025 Jun;105(7):1545-1551. doi: 10.1002/ccd.31491. Epub 2025 Mar 13.
Nakase M, Tomii D, Maznyczka A, Heg D, Okuno T, Samim D, Stortecky S, Lanz J, Reineke D, Windecker S, Pilgrim T. Five-year outcomes with self-expanding versus balloon-expandable TAVI in patients with left ventricular systolic dysfunction. Am Heart J. 2025 Feb;280:18-29. doi: 10.1016/j.ahj.2024.10.018. Epub 2024 Nov 12.
Nakase M, Tomii D, Samim D, Grani C, Praz F, Lanz J, Stortecky S, Reineke D, Windecker S, Pilgrim T. Impact of Severity and Extent of Iliofemoral Atherosclerosis on Clinical Outcomes in Patients Undergoing TAVR. JACC Cardiovasc Interv. 2024 Oct 28;17(20):2353-2363. doi: 10.1016/j.jcin.2024.07.009. Epub 2024 Oct 9.
Tomii D, Heg D, Lanz J, Nakase M, Samim D, Stortecky S, Reineke D, Windecker S, Pilgrim T. Renin-Angiotensin System Inhibition in Patients With Myocardial Injury Complicating Transcatheter Aortic Valve Replacement. JACC Adv. 2024 Aug 16;3(9):101212. doi: 10.1016/j.jacadv.2024.101212. eCollection 2024 Sep.
Tomii D, Okuno T, Nakase M, Praz F, Stortecky S, Reineke D, Windecker S, Lanz J, Pilgrim T. Renin-Angiotensin System Inhibition and Cardiac Damage in Patients Undergoing Transcatheter Aortic Valve Replacement. Can J Cardiol. 2024 Dec;40(12):2592-2602. doi: 10.1016/j.cjca.2024.07.019. Epub 2024 Jul 25.
Brunner S, Moccetti F, Loretz L, Conrad N, Bossard M, Attinger-Toller A, Kurmann R, Cuculi F, Wolfrum M, Toggweiler S. The impact of elevated C-reactive protein levels on long-term outcomes of patients undergoing transcatheter aortic valve replacement. Cardiovasc Revasc Med. 2025 Jan;70:71-75. doi: 10.1016/j.carrev.2024.07.002. Epub 2024 Jul 6.
Nakase M, Tomii D, Maznyczka A, Samim D, Lanz J, Praz F, Stortecky S, Reineke D, Windecker S, Pilgrim T. Sex-Specific Differences in Upstream Cardiac Damage in Patients With Aortic Stenosis Undergoing TAVR. JACC Cardiovasc Interv. 2024 May 27;17(10):1252-1264. doi: 10.1016/j.jcin.2024.03.031.
Nakase M, Tomii D, Heg D, Praz F, Stortecky S, Reineke D, Samim D, Lanz J, Windecker S, Pilgrim T. Long-Term Impact of Cardiac Damage Following Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2024 Apr 22;17(8):992-1003. doi: 10.1016/j.jcin.2024.02.011.
Alaour B, Ferrari E, Heg D, Tueller D, Pilgrim T, Muller O, Noble S, Jeger R, Reuthebuch O, Toggweiler S, Templin C, Wenaweser P, Nietlispach F, Taramasso M, Huber C, Roffi M, Windecker S, Stortecky S. Non-Vitamin K Antagonist Versus Vitamin K Antagonist Oral Anticoagulant Agents After Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2024 Feb 12;17(3):405-418. doi: 10.1016/j.jcin.2023.11.038.
Okuno T, Alaour B, Heg D, Tueller D, Pilgrim T, Muller O, Noble S, Jeger R, Reuthebuch O, Toggweiler S, Ferrari E, Templin C, Wenaweser P, Nietlispach F, Taramasso M, Huber C, Roffi M, Windecker S, Stortecky S. Long-Term Risk of Stroke After Transcatheter Aortic Valve Replacement: Insights From the SwissTAVI Registry. JACC Cardiovasc Interv. 2023 Dec 25;16(24):2986-2996. doi: 10.1016/j.jcin.2023.10.021.
Tomii D, Okuno T, Heg D, Nakase M, Lanz J, Praz F, Stortecky S, Reineke D, Windecker S, Pilgrim T. Long-term outcomes of measured and predicted prosthesis-patient mismatch following transcatheter aortic valve replacement. EuroIntervention. 2023 Nov 17;19(9):746-756. doi: 10.4244/EIJ-D-23-00456.
Nakase M, Tomii D, Heg D, Praz F, Stortecky S, Lanz J, Reineke D, Windecker S, Pilgrim T. Association of atrial fibrillation with survival in patients with low-flow low-gradient aortic stenosis with preserved ejection fraction undergoing TAVI. Eur Heart J Qual Care Clin Outcomes. 2024 May 22;10(3):246-255. doi: 10.1093/ehjqcco/qcad045.
Alwan L, Tomii D, Heg D, Okuno T, Lanz J, Praz F, Chong-Nguyen C, Stortecky S, Reineke D, Windecker S, Pilgrim T. Impact of right ventricular-pulmonary arterial coupling on clinical outcomes in patients undergoing transcatheter aortic valve implantation. Cardiovasc Revasc Med. 2023 Nov;56:27-34. doi: 10.1016/j.carrev.2023.05.008. Epub 2023 May 16.
Okuno T, Tomii D, Lanz J, Heg D, Praz F, Stortecky S, Reineke D, Windecker S, Pilgrim T. 5-Year Outcomes With Self-Expanding vs Balloon-Expandable Transcatheter Aortic Valve Replacement in Patients With Small Annuli. JACC Cardiovasc Interv. 2023 Feb 27;16(4):429-440. doi: 10.1016/j.jcin.2022.11.032.
Tomii D, Okuno T, Lanz J, Stortecky S, Reineke D, Windecker S, Pilgrim T. Valve-in-valve TAVI and risk of coronary obstruction: Validation of the VIVID classification. J Cardiovasc Comput Tomogr. 2023 Mar-Apr;17(2):105-111. doi: 10.1016/j.jcct.2023.01.042. Epub 2023 Feb 6.
Tomii D, Okuno T, Lanz J, Stortecky S, Windecker S, Pilgrim T. Aortic annulus ellipticity and outcomes after transcatheter aortic valve implantation. Catheter Cardiovasc Interv. 2023 Jan;101(1):199-208. doi: 10.1002/ccd.30507. Epub 2022 Dec 1.
Okuno T, Demirel C, Tomii D, Heg D, Haner J, Siontis GCM, Lanz J, Raber L, Strotecky S, Furholz M, Praz F, Windecker S, Pilgrim T. Long-term risk of unplanned percutaneous coronary intervention after transcatheter aortic valve replacement. EuroIntervention. 2022 Nov 18;18(10):797-803. doi: 10.4244/EIJ-D-22-00342.
Mergen V, Sartoretti T, Baer-Beck M, Schmidt B, Petersilka M, Wildberger JE, Euler A, Eberhard M, Alkadhi H. Ultra-High-Resolution Coronary CT Angiography With Photon-Counting Detector CT: Feasibility and Image Characterization. Invest Radiol. 2022 Dec 1;57(12):780-788. doi: 10.1097/RLI.0000000000000897. Epub 2022 May 31.
Tomii D, Okuno T, Heg D, Pilgrim T, Windecker S. Long-term outcomes of new-onset conduction abnormalities following transcatheter aortic valve implantation. Arch Cardiovasc Dis. 2022 Apr;115(4):214-224. doi: 10.1016/j.acvd.2022.04.005. Epub 2022 Apr 22.
Okuno T, Tomii D, Buffle E, Lanz J, Ryffel C, Demirel C, Hashemi S, Hagemeyer D, Papadis A, Heg D, Praz F, Stortecky S, Windecker S, Pilgrim T. Transcatheter aortic valve implantation in patients with rheumatic aortic stenosis. Heart. 2022 Jul 13;108(15):1225-1233. doi: 10.1136/heartjnl-2021-320531.
Tomii D, Okuno T, Demirel C, Praz F, Lanz J, Stortecky S, Windecker S, Pilgrim T. Impact of First-Phase Ejection Fraction on Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation. Cardiovasc Revasc Med. 2022 Sep;42:55-61. doi: 10.1016/j.carrev.2022.02.023. Epub 2022 Feb 26.
Tomii D, Okuno T, Heg D, Lanz J, Praz F, Stortecky S, Windecker S, Pilgrim T. Validation of the VARC-3 Technical Success Definition in Patients Undergoing TAVR. JACC Cardiovasc Interv. 2022 Feb 28;15(4):353-364. doi: 10.1016/j.jcin.2021.11.013. Epub 2022 Jan 31.
Mergen V, Sartoretti T, Klotz E, Schmidt B, Jungblut L, Higashigaito K, Manka R, Euler A, Kasel M, Eberhard M, Alkadhi H. Extracellular Volume Quantification With Cardiac Late Enhancement Scanning Using Dual-Source Photon-Counting Detector CT. Invest Radiol. 2022 Jun 1;57(6):406-411. doi: 10.1097/RLI.0000000000000851. Epub 2022 Jan 21.
Okuno T, Tomii D, Heg D, Lanz J, Praz F, Stortecky S, Reineke D, Windecker S, Pilgrim T. Five-year outcomes of mild paravalvular regurgitation after transcatheter aortic valve implantation. EuroIntervention. 2022 May 15;18(1):33-42. doi: 10.4244/EIJ-D-21-00784.
Tomii D, Okuno T, Heg D, Grani C, Lanz J, Praz F, Stortecky S, Windecker S, Pilgrim T, Reineke D. Sinus of Valsalva Dimension and Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation. Am Heart J. 2022 Feb;244:94-106. doi: 10.1016/j.ahj.2021.11.004. Epub 2021 Nov 14.
Tomii D, Okuno T, Praz F, Heg D, Wild MG, Lanz J, Stortecky S, Reineke D, Windecker S, Pilgrim T. Potential Candidates for Transcatheter Tricuspid Valve Intervention After Transcatheter Aortic Valve Replacement: Predictors and Prognosis. JACC Cardiovasc Interv. 2021 Oct 25;14(20):2246-2256. doi: 10.1016/j.jcin.2021.07.030. Epub 2021 Sep 29.
Okuno T, Lanz J, Stortecky S, Heg D, Bernhard B, Grani C, Huber A, Praz F, Raber L, Valgimigli M, Siontis GCM, Windecker S, Pilgrim T. Clinical impact of left atrial appendage filling defects in patients undergoing transcatheter aortic valve implantation. Eur Heart J Cardiovasc Imaging. 2022 Sep 10;23(10):1354-1364. doi: 10.1093/ehjci/jeab142.
Eberhard M, Hinzpeter R, Schonenberger ALN, Euler A, Kuzo N, Reeve K, Stahli BE, Kasel AM, Manka R, Tanner FC, Alkadhi H. Incremental Prognostic Value of Coronary Artery Calcium Score for Predicting All-Cause Mortality after Transcatheter Aortic Valve Replacement. Radiology. 2021 Oct;301(1):105-112. doi: 10.1148/radiol.2021204623. Epub 2021 Aug 3.
Okuno T, Heg D, Lanz J, Praz F, Brugger N, Stortecky S, Windecker S, Pilgrim T. Refined staging classification of cardiac damage associated with aortic stenosis and outcomes after transcatheter aortic valve implantation. Eur Heart J Qual Care Clin Outcomes. 2021 Oct 28;7(6):532-541. doi: 10.1093/ehjqcco/qcab041.
Attinger-Toller A, Ferrari E, Tueller D, Templin C, Muller O, Nietlispach F, Toggweiler S, Noble S, Roffi M, Jeger R, Huber C, Carrel T, Pilgrim T, Wenaweser P, Togni M, Cook S, Heg D, Windecker S, Goy JJ, Stortecky S. Age-Related Outcomes After Transcatheter Aortic Valve Replacement: Insights From the SwissTAVI Registry. JACC Cardiovasc Interv. 2021 May 10;14(9):952-960. doi: 10.1016/j.jcin.2021.01.042. Epub 2021 Apr 14.
Okuno T, Corpataux N, Spano G, Grani C, Heg D, Brugger N, Lanz J, Praz F, Stortecky S, Siontis GCM, Windecker S, Pilgrim T. True-severe stenosis in paradoxical low-flow low-gradient aortic stenosis: outcomes after transcatheter aortic valve replacement. Eur Heart J Qual Care Clin Outcomes. 2021 Jul 21;7(4):366-377. doi: 10.1093/ehjqcco/qcab010.
Sweda R, Dobner S, Heg D, Lanz J, Malebranche D, Langhammer B, Okuno T, Praz F, Raber L, Valgimigli M, Reineke D, Pilgrim T, Windecker S, Stortecky S. Discharge Location and Outcomes After Transcatheter Aortic Valve Implantation. Am J Cardiol. 2021 Feb 1;140:95-102. doi: 10.1016/j.amjcard.2020.10.058. Epub 2020 Nov 2.
Okuno T, Brugger N, Asami M, Heg D, Siontis GCM, Winkel MG, Lanz J, Grani C, Huber A, Stortecky S, George I, Kodali S, Pilgrim T, Windecker S, Khalique OK, Praz F. Clinical impact of mitral calcium volume in patients undergoing transcatheter aortic valve implantation. J Cardiovasc Comput Tomogr. 2021 Jul-Aug;15(4):356-365. doi: 10.1016/j.jcct.2020.10.003. Epub 2020 Oct 21.
Okuno T, Hagemeyer D, Brugger N, Ryffel C, Heg D, Lanz J, Praz F, Stortecky S, Raber L, Roten L, Reichlin T, Windecker S, Pilgrim T. Valvular and Nonvalvular Atrial Fibrillation in Patients Undergoing Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2020 Sep 28;13(18):2124-2133. doi: 10.1016/j.jcin.2020.05.049.
Okuno T, Asami M, Heg D, Lanz J, Praz F, Hagemeyer D, Brugger N, Grani C, Huber A, Spirito A, Raber L, Stortecky S, Windecker S, Pilgrim T. Impact of Left Ventricular Outflow Tract Calcification on Procedural Outcomes After Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2020 Aug 10;13(15):1789-1799. doi: 10.1016/j.jcin.2020.04.015.
Stortecky S, Heg D, Tueller D, Pilgrim T, Muller O, Noble S, Jeger R, Toggweiler S, Ferrari E, Taramasso M, Maisano F, Hoeller R, Wenaweser P, Nietlispach F, Widmer A, Huber C, Roffi M, Carrel T, Windecker S, Conen A. Infective Endocarditis After Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. 2020 Jun 23;75(24):3020-3030. doi: 10.1016/j.jacc.2020.04.044.
Muller O, Fournier S, Pilgrim T, Heg D, Noble S, Jeger R, Toggweiler S, Taramasso M, Windecker S, Stortecky S; SwissTAVI Investigators. Local Versus General Anesthesia for Transcatheter Aortic Valve Replacement: A SwissTAVI Registry Analysis. JACC Cardiovasc Interv. 2019 Sep 23;12(18):1874-1876. doi: 10.1016/j.jcin.2019.05.047. No abstract available.
Baumann F, Obeid S, Gilhofer T, Siegrist P, von Spiczak J, Luscher TF, Binder RK. Right coronary artery motion analysis: a novel method to measure right ventricular systolic function by selective coronary angiography. Int J Cardiovasc Imaging. 2019 Sep;35(9):1557-1561. doi: 10.1007/s10554-019-01606-9. Epub 2019 May 2.
Asami M, Pilgrim T, Lanz J, Heg D, Franzone A, Piccolo R, Langhammer B, Praz F, Raber L, Valgimigli M, Roost E, Windecker S, Stortecky S. Prognostic Relevance of Left Ventricular Myocardial Performance After Transcatheter Aortic Valve Replacement. Circ Cardiovasc Interv. 2019 Jan;12(1):e006612. doi: 10.1161/CIRCINTERVENTIONS.118.006612.
Asami M, Stortecky S, Praz F, Lanz J, Raber L, Franzone A, Piccolo R, Siontis GCM, Heg D, Valgimigli M, Wenaweser P, Roost E, Windecker S, Pilgrim T. Prognostic Value of Right Ventricular Dysfunction on Clinical Outcomes After Transcatheter Aortic Valve Replacement. JACC Cardiovasc Imaging. 2019 Apr;12(4):577-587. doi: 10.1016/j.jcmg.2017.12.015. Epub 2018 Feb 14.
Binder RK, Stortecky S, Heg D, Tueller D, Jeger R, Toggweiler S, Pedrazzini G, Amann FW, Ferrari E, Noble S, Nietlispach F, Maisano F, Raber L, Roffi M, Grunenfelder J, Juni P, Huber C, Windecker S, Wenaweser P. Procedural Results and Clinical Outcomes of Transcatheter Aortic Valve Implantation in Switzerland: An Observational Cohort Study of Sapien 3 Versus Sapien XT Transcatheter Heart Valves. Circ Cardiovasc Interv. 2015 Oct;8(10):e002653. doi: 10.1161/CIRCINTERVENTIONS.115.002653.
Wenaweser P, Stortecky S, Heg D, Tueller D, Nietlispach F, Falk V, Pedrazzini G, Jeger R, Reuthebuch O, Carrel T, Raber L, Amann FW, Ferrari E, Toggweiler S, Noble S, Roffi M, Gruenenfelder J, Juni P, Windecker S, Huber C. Short-term clinical outcomes among patients undergoing transcatheter aortic valve implantation in Switzerland: the Swiss TAVI registry. EuroIntervention. 2014 Dec;10(8):982-9. doi: 10.4244/EIJV10I8A166.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
May 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
May 23, 2024
Record last verified: 2024-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: